Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12318257 | 0.84 | HDAC4 (0.32) | CA12CA2CA9HDAC4HDAC6 | |
| SCHEMBL13859730 | 0.84 | HDAC4 (0.31) | CA12CA2CA9HDAC4HDAC6 | |
| SCHEMBL14615431 | 0.84 | HDAC4 (0.31) | CA12CA2CA9HDAC4HDAC6 | |
| SCHEMBL13859734 | 0.83 | CA12 (0.33) | CA12CA2CA9HDAC4HDAC6 | |
| SCHEMBL12270636 | 0.83 | HDAC4 (0.32) | CA12CA2CA9HDAC4HDAC6 | |
| SCHEMBL774368 | 0.82 | CA12 (0.36) | CA12CA2CA9HDAC4HDAC6 | |
| SCHEMBL772715 | 0.82 | CA12 (0.38) | CA12CA2CA9HDAC4HDAC6 | |
| SCHEMBL773837 | 0.80 | CA12 (0.39) | CA12CA2CA9HDAC4HDAC6 | |
| SCHEMBL775360 | 0.80 | HDAC4 (0.33) | CA12CA2CA9HDAC4HDAC6 | |
| SCHEMBL774346 | 0.79 | CA12 (0.34) | CA12CA2CA9HDAC4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318656-B2 | Production processes and systems, compositions, surfactants, monomer units, metal complexes, phosphate esters, glycols, aqueous film forming foams, and foam stabilizers | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120071689-A1 | PRODUCTION PROCESSES AND SYSTEMS, COMPOSITIONS, SURFACTANTS, MONOMER UNITS, METAL COMPLEXES, PHOSPHATE ESTERS, GLYCOLS, AQUEOUS FILM FORMING FOAMS, AND FOAM STABILIZERS | E.I. DU PONT DE NEMOURS AND COMPANY CHEMTURA CORPORATION (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071689-A1 | PRODUCTION PROCESSES AND SYSTEMS, COMPOSITIONS, SURFACTANTS, MONOMER UNITS, METAL COMPLEXES, PHOSPHATE ESTERS, GLYCOLS, AQUEOUS FILM FORMING FOAMS, AND FOAM STABILIZERS | FOS, AFF4, AFF1 | CA12 2399/4885CA2 1820/4885CA9 3510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.